Biotronik is beginning the launch of its newly approved Ilesto line of thinner, smaller cardiac implants with the remotely monitored Ilesto DX platform, the company announced today.
The Ilesto line of implants is 15% smaller and requires 29% fewer components than its predecessors, Biotronik said, and the DX devices allow physicians to monitor atrial information and possibly diagnose previously undetected instance of atrial fibrillation.
"The rapid adoption of the DX System is a clear example of the market shift towards quality outcomes and the right technology for the patient," sales & marketing executive vice president Paul Woodstock said in prepared remarks. "We have already captured more than 10% of de novo implants, and with the launch of Ilesto, we expect this number to increase."
Biotronik in May 2013 won FDA approval for the Ilesto 7 suite of devices, saying at the time that it planned to respond to "unprecedented demand for this novel category of device."
The DX technology in particular, which Biotronik calls the 1st defibrillator system capable of providing full atrial diagnostic readings with a single specialized lead, has "surpassed Biotronik’s ambitious expectations for customer adoption since its launch in February 2013," according to a press release.
The German medical device titan just last month released new study results touting the benefits of its remote monitoring technology, saying that patients with implant-based monitoring showed lower mortality rates compared with patients receiving standard care.
"Biotronik home monitoring allows physicians to facilitate early detection of clinically relevant events or crucial trends in cardiac device patients. They then have enough notice to intervene in time, thereby preventing serious or even fatal events and effectively supporting the management of heart failure patients," study coordinating investigator Dr. Gerhard Hindricks said.
